Vir Biotechnology
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-04-07
- Employees
- 587
- Market Cap
- -
- Website
- http://www.vir.bio
- Introduction
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
Tobevibart, Elebsiran Receive FDA Breakthrough Therapy Designation for Chronic HDV
Vir Biotechnology's tobevibart and elebsiran received FDA Breakthrough Therapy and EMA PRIME designations for treating chronic hepatitis delta (CHD), supported by positive SOLSTICE trial data. The combination therapy rapidly suppresses hepatitis delta virus (HDV) to undetectable levels, with 80% of participants in the rollover cohort achieving no detectable viral RNA by week 60. The phase 3 ECLIPSE program is planned for 2025.
Vir Biotechnology's drugs receive FDA and EMA nods
Vir Biotechnology's tobevibart and elebsiran granted Breakthrough Therapy and PRIME designations for chronic hepatitis delta treatment. Phase 2 SOLSTICE trial results show potential to suppress hepatitis delta virus. Company plans Phase 3 ECLIPSE program for 2025. Analysts revise earnings upwards despite stock decline.
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME
Vir Biotechnology receives FDA Breakthrough Therapy and EMA PRIME designations for tobevibart and elebsiran in chronic hepatitis delta, supported by Phase 2 SOLSTICE trial data. Phase 3 ECLIPSE program to start in H1 2025.
Related Clinical Trials:
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA
Vir Biotechnology announced that tobevibart and elebsiran received FDA Breakthrough Therapy and EMA PRIME designations for treating chronic hepatitis delta (CHD), supported by Phase 2 SOLSTICE trial data. The Phase 3 ECLIPSE program will start in H1 2025.
Related Clinical Trials:
Vir's Hepatitis Delta Treatment Earns FDA Breakthrough & EMA PRIME Status After Strong Trial Data
Vir Biotechnology received FDA Breakthrough Therapy and EMA PRIME designations for tobevibart and elebsiran in treating chronic hepatitis delta (CHD), based on positive Phase 2 SOLSTICE trial data. The company plans to start Phase 3 ECLIPSE trials in H1 2025, aiming to address the unmet need for CHD treatment.
Related Clinical Trials:
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
Vir Biotechnology's tobevibart and elebsiran receive FDA Breakthrough Therapy and EMA PRIME designations for chronic hepatitis delta treatment, supported by Phase 2 SOLSTICE trial data. Phase 3 ECLIPSE program to start in 2025.
Related Clinical Trials:
Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Acquired by Charles Schwab Investment
Charles Schwab Investment Management increased its Vir Biotechnology stake by 13.6% in Q3, owning 1,134,276 shares worth $8.5M. Other investors also adjusted their positions. Analysts set new price targets, with an average 'Moderate Buy' rating and $36.40 target. Vir Biotechnology's stock opened at $8.09, with a market cap of $1.11B. The company reported a Q3 loss of $1.56 per share, missing estimates, and revenue of $2.38M, down 9.8% YoY. Vir Biotechnology focuses on developing therapeutic products for serious infectious diseases.
© Copyright 2024. All Rights Reserved by MedPath